Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Cell Therapy Asia 2018

Michael Bennett's Biography



Michael Bennett, Director of Business Development, Cell and Gene Therapy Catapult

Michael Bennett is the Director of Business Development at the Cell and Gene Therapy Catapult and a member of the executive management team. In addition to managing worldwide business development, he is responsible for the intellectual property portfolio, legal and contractual obligations of the Cell and Gene Therapy Catapult. An experienced negotiator who has closed tens of multi-million US dollar revenue generating agreements such as in and out licences and settlement agreements.

Previously Michael has held a number of executive management positions and was the Vice President of Business Development and Licensing for Oxford Gene Technology Ltd, Vice President of Sales and Marketing for Molecular Sensing Plc, Market Manager for Roche Diagnostics and Product Manager for Hybaid after spending four years as a post-doctoral researcher at the University of Bristol and the Royal Free Hospital in London.

He is a chartered biologist (CBiol) holds a BSc (Hons) in Biology from the University of the West of Scotland along with a doctorate (D.Phil) from the University of Oxford.

Michael Bennett Image

Commercialization of Cell Therapies – Laboratory to Bedside

Friday, 7 December 2018 at 15:00

Add to Calendar ▼2018-12-07 15:00:002018-12-07 16:00:00Europe/LondonCommercialization of Cell Therapies – Laboratory to BedsideCell Therapy Asia 2018 in Kobe, JapanKobe, JapanSELECTBIOenquiries@selectbiosciences.com

There are many teams of scientists working diligently in the broad field of regenerative medicine.  The goal of much of this work is to create new medicines that have the potential to cure debilitating diseases that conventional small molecule medicines cannot.  In my presentation I will discuss some of the challenges facing us all within regenerative medicine and some of the solutions that the cell and gene therapy catapult has seen implemented around the world to assist the commercialisation of promising laboratory science through pre-clinical testing, clinical trial and to the patient bedside.


Add to Calendar ▼2018-12-06 00:00:002018-12-07 00:00:00Europe/LondonCell Therapy Asia 2018Cell Therapy Asia 2018 in Kobe, JapanKobe, JapanSELECTBIOenquiries@selectbiosciences.com